Европска Унија - Чешки - EMA (European Medicines Agency)

sanofi winthrop industrie - teriflunomid - roztroušená skleróza - selektivní imunosupresiva - aubagio is indicated for the treatment of adult patients and paediatric patients aged 10 years and older with relapsing remitting multiple sclerosis (ms) (please refer to section 5. 1 for important information on the population for which efficacy has been established).

Европска Унија - Чешки - EMA (European Medicines Agency)

novo nordisk a/s - semaglutid - obesity; overweight - preparáty proti obezitě, diety - wegovy is indicated as an adjunct to a reduced-calorie diet and increased physical activity for weight management, including weight loss and weight maintenance, in adults with an initial body mass index (bmi) of- ≥30 kg/m² (obesity), or- ≥27 kg/m² to.

Европска Унија - Чешки - EMA (European Medicines Agency)

bial portela & companhia s.a. - opicapone - parkinsonova choroba - antiparkinsonické léky - ontilyv is indicated as adjunctive therapy to preparations of levodopa/ dopa decarboxylase inhibitors (ddci) in adult patients with parkinson’s disease and end-of-dose motor fluctuations who cannot be stabilised on those combinations.

Европска Унија - Чешки - EMA (European Medicines Agency)

mylan pharmaceuticals limited - teriflunomid - roztroušená skleróza, relaps-remitentní - imunosupresiva - teriflunomide mylan is indicated for the treatment of adult patients and paediatric patients aged 10 years and older (body weight > 40 kg) with relapsing remitting multiple sclerosis (ms) (please refer to section 5. 1 of the smpc for important information on the population for which efficacy has been established).

Европска Унија - Чешки - EMA (European Medicines Agency)

accord healthcare s.l.u. - teriflunomid - roztroušená skleróza, relaps-remitentní - imunosupresiva, selektivní imunosupresiva - teriflunomide accord is indicated for the treatment of adult patients and paediatric patients aged 10 years and older with relapsing remitting multiple sclerosis (ms) (please refer to section 5. 1 for important information on the population for which efficacy has been established).

Чешка - Чешки - SUKL (Státní ústav pro kontrolu léčiv)

sanofi pasteur, lyon array - 13899 inaktivovanÝ virus hepatitidy a - injekční suspenze v předplněné injekční stříkačce - 160eu - hepatitida a, inaktivovanÝ celÝ virus

Чешка - Чешки - SUKL (Státní ústav pro kontrolu léčiv)

chiesi farmaceutici s.p.a., parma array - 14336 fosfolipidy z praseČÍch plic - suspenze k endotracheopulmonální instilaci - 80mg/ml - pŘÍrodnÍ fosfolipidy

Европска Унија - Чешки - EMA (European Medicines Agency)

novartis europharm limited - nepafenac - pain, postoperative; ophthalmologic surgical procedures - oftalmologické látky - nevanac is indicated for: , prevention and treatment of postoperative pain and inflammation associated with cataract surgery;, reduction in the risk of postoperative macular oedema associated with cataract surgery in diabetic patients.

Чешка - Чешки - SUKL (Státní ústav pro kontrolu léčiv)

orpha-devel handels und vertriebs gmbh, purkersdorf array - 13217 esmolol-hydrochlorid - injekční roztok - 10mg/ml - esmolol

Европска Унија - Чешки - EMA (European Medicines Agency)

merck sharp & dohme b.v.  - pneumococcal polysaccharide conjugate vaccine (adsorbed) - pneumokokové infekce - pneumococcus, purified polysaccharides antigen conjugated - vaxneuvance is indicated for active immunisation for the prevention of invasive disease, pneumonia and acute otitis media caused by streptococcus pneumoniae in infants, children and adolescents from 6 weeks to less than 18 years of age. vaxneuvance is indicated for active immunisation for the prevention of invasive disease and pneumonia caused by streptococcus pneumoniae in individuals 18 years of age and older. viz kapitoly 4. 4 a 5. 1 pro informace o ochraně proti specifickým pneumokokovým sérotypům. the use of vaxneuvance should be in accordance with official recommendations.